Back to newsroom
News
Results of Clinical Trial PA.6 Announced in Chicago

June 9, 2019

Image of RASONQUE (daraxonrasib) bottle and carton packaging.

Clinical trial results performed in Canada and France using mFOLFIRINOX have shown that patients who undergo surgical removal of pancreatic cancer cells lived on average, 20 months longer than those who received gemicitabine. – Global News

Be part of the force driving answers for this devastating disease.

Make a donation towards pancreatic cancer research and support programs.

donate today

Keep in the loop:

Read more PCNA News:

discover more

Research
Six Months is a Start

Research
We Asked. You Shared. Here’s What We Do Next.

August 19, 2026

Research
It's Probably Just Menopause...